Examkin

Soru

Zorluk: ZorNeoplastic Processes

A 31-year-old male is admitted to the intensive care unit with acute-onset diffuse mucosal bleeding, petechiae across his torso, and severe fatigue. Vital signs are temperature 37.8∘C37.8^\circ\text{C} (100.0∘F100.0^\circ\text{F}), blood pressure 110/70 mmHg110/70\text{ mmHg}, heart rate 105/min105/\text{min}, and respiratory rate 18/min18/\text{min}. Laboratory studies show:

- Leukocytes: 2,100/μL2,100/\mu\text{L}
- Hemoglobin: 8.4 g/dL8.4\text{ g/dL}
- Platelets: 24,000/μL24,000/\mu\text{L}
- Prothrombin time: 19 seconds19\text{ seconds}
- Partial thromboplastin time: 46 seconds46\text{ seconds}
- Fibrinogen: 85 mg/dL85\text{ mg/dL}
- D-dimer: >10,000 ng/mL>10,000\text{ ng/mL}

Peripheral blood smear reveals numerous abnormal promyelocytes with bilobed nuclei, abundant granules, and multiple needle-like cytoplasmic inclusions. The underlying neoplastic process involves a chromosomal translocation that creates a fusion protein, which abnormally represses gene transcription. Based on the suspected molecular pathology, which of the following is the most appropriate next step in management?

  1. Administer a retinoid derivative immediately without awaiting cytogenetic confirmationCevap
  2. B
    Obtain a bone marrow aspirate and biopsy to confirm the genetic mutation before initiating targeted therapy
  3. C
    Initiate standard induction chemotherapy with cytarabine and an anthracycline to rapidly achieve cellular lysis of the neoplastic clones
  4. D
    Administer fresh frozen plasma and cryoprecipitate to correct the coagulopathy, withholding antineoplastic agents until bleeding stops
  5. E
    Schedule urgent leukapheresis to prevent microvascular occlusion from the circulating neoplastic cells

Cevap

Administer a retinoid derivative immediately without awaiting cytogenetic confirmation.
The patient's presentation of severe bleeding, coagulopathy (prolonged PT/PTT, low fibrinogen, high D-dimer), and a peripheral smear showing atypical promyelocytes with multiple Auer rods (needle-like inclusions) is highly suspicious for acute promyelocytic leukemia (APL). APL is driven by the t(15;17) translocation, which forms the PML-RARA fusion protein. This complex halts myeloid differentiation and causes the accumulation of promyelocytes containing dense primary granules. The release of these procoagulant granules causes disseminated intravascular coagulation (DIC), which is the leading cause of early mortality in these patients. The correct immediate management is the administration of all-trans retinoic acid (ATRA), a retinoid derivative. ATRA overcomes the differentiation block by binding the retinoic acid receptor component of the fusion protein, leading to its degradation and allowing the malignant cells to differentiate into mature neutrophils. This targeted intervention rapidly resolves the coagulopathy. Due to the high risk of catastrophic hemorrhage, ATRA must be given empirically based on morphological and clinical suspicion alone; waiting for cytogenetic or molecular confirmation is a dangerous delay.

Adım Adım Çözüm

1
Analyze the clinical presentation, laboratory values, and peripheral blood smear.
The patient presents with severe bleeding, pancytopenia, prolonged coagulation times, very low fibrinogen, and elevated D-dimer, indicating disseminated intravascular coagulation (DIC). The smear shows abnormal promyelocytes with Auer rods.
This combination of DIC and malignant promyelocytes is the hallmark of acute promyelocytic leukemia (APL).
2
Identify the underlying molecular mechanism driving the disease.
APL is driven by the t(15;17) translocation, creating the PML-RARA fusion protein, which acts as a transcriptional repressor blocking myeloid differentiation.
Understanding the genetic driver explains both the accumulation of promyelocytes and the rationale for targeted therapy.
3
Determine the most critical, immediate step in management based on this pathophysiology.
The primary cause of early death in APL is fatal hemorrhage due to DIC. All-trans retinoic acid (ATRA) acts by degrading the PML-RARA complex and forcing the cells to differentiate, which rapidly ameliorates the coagulopathy.
Because of the high risk of early mortality, empiric administration of ATRA is the standard of care and must be initiated based on clinical and morphological suspicion alone, prior to genetic confirmation.

Anahtar Kavram

In patients with suspected acute promyelocytic leukemia (APL) presenting with disseminated intravascular coagulation, the most critical next step is the immediate, empiric administration of a retinoid derivative (ATRA) to induce cellular differentiation and halt the coagulopathy, without waiting for definitive cytogenetic confirmation.
Bu soruyu puanla

Konular

Neoplastic Processes

Bu konudan daha fazla soru